The Filing Desk

Immunocore vs Krystal Biotech

Immunocore IMCR · Krystal Biotech KRYS · Biotechnology

Immunocore reported revenue of $400 million in fiscal 2025, about the same as Krystal Biotech's $389 million in fiscal 2025. Immunocore's revenue grew 28.9% in its latest year, and Krystal Biotech's grew 33.9%. Immunocore had an operating margin of -11.3%, against 41.5% at Krystal Biotech. Free cash flow was −$15 million at Immunocore and $189 million at Krystal Biotech.

Side by side

ImmunocoreKrystal Biotech
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$400M$389M
Revenue growth28.9%33.9%
Revenue growth a year, last 5 years——
Gross margin98.7%—
Operating margin−11.3%41.5%
Net margin−8.9%52.6%
Free cash flow−$15M$189M
Free cash flow margin−3.8%48.5%
Return on capital—43.6%
Net debt to EBITDA—−5.0x
Dividends and buybacks$0M$0M
Change in diluted share count0.7%0.7%
Last close$26.63$315.82
P/E at the last close—42.9×
Insider trades, last 12 monthssold $5.6 millionsold $105.3 million
Piotroski F-score—5 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ImmunocoreKrystal Biotech
Operating margin
Percent of revenue
ImmunocoreKrystal Biotech
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ImmunocoreKrystal Biotech

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Immunocore and Krystal Biotech pages.